DK52089D0 - Middel til behandling af nyresygdomme - Google Patents

Middel til behandling af nyresygdomme

Info

Publication number
DK52089D0
DK52089D0 DK052089A DK52089A DK52089D0 DK 52089 D0 DK52089 D0 DK 52089D0 DK 052089 A DK052089 A DK 052089A DK 52089 A DK52089 A DK 52089A DK 52089 D0 DK52089 D0 DK 52089D0
Authority
DK
Denmark
Prior art keywords
treatment
medicine
kidney diseases
igf
renal
Prior art date
Application number
DK052089A
Other languages
English (en)
Other versions
DK52089A (da
DK169232B1 (da
Inventor
Ernst Rudolf Froesch
Hans-Peter Guler
Christoph Schmid
Juergen Zapf
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of DK52089D0 publication Critical patent/DK52089D0/da
Publication of DK52089A publication Critical patent/DK52089A/da
Application granted granted Critical
Publication of DK169232B1 publication Critical patent/DK169232B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
DK052089A 1988-02-05 1989-02-03 Anvendelse af IGF I til fremstilling af et farmaceutisk præparat til behandling af nyresygdomme DK169232B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP88810071 1988-02-05
EP88810071 1988-02-05

Publications (3)

Publication Number Publication Date
DK52089D0 true DK52089D0 (da) 1989-02-03
DK52089A DK52089A (da) 1989-08-06
DK169232B1 DK169232B1 (da) 1994-09-19

Family

ID=8200570

Family Applications (1)

Application Number Title Priority Date Filing Date
DK052089A DK169232B1 (da) 1988-02-05 1989-02-03 Anvendelse af IGF I til fremstilling af et farmaceutisk præparat til behandling af nyresygdomme

Country Status (10)

Country Link
US (1) US5106832A (da)
EP (1) EP0327503B1 (da)
JP (1) JP2783825B2 (da)
KR (1) KR0131088B1 (da)
AT (1) ATE86496T1 (da)
AU (1) AU621583B2 (da)
CA (1) CA1336400C (da)
DE (1) DE68905203T2 (da)
DK (1) DK169232B1 (da)
ZA (1) ZA89813B (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128320A (en) * 1990-01-18 1992-07-07 Genentech, Inc. Method of restoring normal growth, weight gain or lean body mass in patients with glucocorticoid excess by administering igf-i
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5374620A (en) * 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
AU3812993A (en) * 1992-03-24 1993-10-21 Synergen, Inc. Refolding and purification of insulin-like growth factor I
US5273961A (en) * 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
JPH09509141A (ja) * 1993-11-15 1997-09-16 セルトリックス ファーマシューティカルズ，インコーポレイテッド Ｉｇｆ‐ｉおよびｉｇｆｂｐ‐３を投与することによる腎臓疾患処置の方法
US6812208B2 (en) 1993-12-23 2004-11-02 Neuronz Ltd. Methods to improve neural outcome
US5728676A (en) * 1994-09-08 1998-03-17 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
US5837675A (en) * 1995-02-03 1998-11-17 Brox; Alan G. Synergistic effect of insulin-like growth factor-I and erythropoietin
US5565428A (en) * 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
JPH0995455A (ja) * 1995-09-29 1997-04-08 Sumitomo Pharmaceut Co Ltd 腎機能改善剤
US5985830A (en) * 1996-09-16 1999-11-16 Dalhousie University Use of IGF-I for the treatment of kidney disorders
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US20030069177A1 (en) * 2000-05-16 2003-04-10 Genentech, Inc. Method for treating cartilage disorders
US7074762B2 (en) * 1998-01-05 2006-07-11 Washington University Composition and method for improving function of embryonic kidney transplants
CA2356109C (en) 1999-01-06 2008-04-22 Genentech, Inc. Insulin-like growth factor (igf) i mutant variants
DE60042550D1 (de) * 1999-01-06 2009-08-27 Genentech Inc Mutierte varianten des insulin-ähnlichen wachstumsfaktor i (igf-i)
CN100439397C (zh) * 2001-02-09 2008-12-03 基因技术股份有限公司 Igf-1的结晶
ATE435852T1 (de) 2001-05-24 2009-07-15 Neuren Pharmaceuticals Ltd Gpe-analoga und peptidomimetika
US7714020B2 (en) * 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
US20070004641A1 (en) * 2001-05-24 2007-01-04 Neuren Pharmaceuticals Limited Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate
US7605177B2 (en) * 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
EP1791551B1 (en) * 2004-08-30 2020-02-26 Ipsen Biopharmaceuticals, Inc. Method and device for diagnosing and treating insulin-like growth factor deficiency disorders
WO2021005604A1 (en) 2019-07-11 2021-01-14 Opko Biologics Ltd. Long-acting igf-1 or igf-1 variants and methods of producing same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3486216T2 (de) * 1983-04-25 1994-02-17 Chiron Corp Hybrid-DNS-Synthesis von reifen insulinähnlichen Wachstumsfaktoren.

Also Published As

Publication number Publication date
JP2783825B2 (ja) 1998-08-06
DE68905203D1 (de) 1993-04-15
DK52089A (da) 1989-08-06
AU2899889A (en) 1989-08-10
ATE86496T1 (de) 1993-03-15
CA1336400C (en) 1995-07-25
JPH01226827A (ja) 1989-09-11
ZA89813B (en) 1989-09-27
KR890012666A (ko) 1989-09-18
DK169232B1 (da) 1994-09-19
US5106832A (en) 1992-04-21
EP0327503B1 (en) 1993-03-10
DE68905203T2 (de) 1993-07-22
KR0131088B1 (ko) 1998-04-17
EP0327503A1 (en) 1989-08-09
AU621583B2 (en) 1992-03-19

Similar Documents

Publication Publication Date Title
DK52089A (da) Middel til behandling af nyresygdomme
ATE254926T1 (de) Verwendung eines consensus-interferons zur reduzierung der nebeneffekte in der interferon behandlung von viralen hepatiten.
DE69625691D1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
ATE65505T1 (de) Biologisch aktive fragmente von humanem antihaemophiliefaktor, methode zu ihrer herstellung und pharmazeutische praeparate.
DE69230046D1 (de) 2-Bromomelatonin zur Behandlung von Schlafstörungen
DK184890A (da) Anvendelse af anti-t-celle-immunotoxin til fremstilling af farmaceutiske praeparater til behandling af autoimmune sygdomme
ATE81984T1 (de) Verwendung von granulozyt-makrophagen-kolonie erregenden faktor zur herstellung eines medikaments zur behandlung von bakterieller krankheiten.
FI971420A0 (fi) Menetelmä diabetes mellituksen hoitamiseksi KGF:ää käyttämällä
DE3682229D1 (de) Zur stimulierung der traenensekretion verwendbare pharmazeutische praeparate.
DK47089A (da) Middel med oedelaeggende virkning paa maligne tumorer, fremgangsmaade til fremstilling af saadanne midler og anvendelse af disse til terapeutisk behandling af cancer
ATE121100T1 (de) Ein neues thrombomodulin ähnliches glykoprotein erhältlich aus harn.
DK0851762T3 (da) Farmaceutiske kombinationspræparater, som indeholder erythropoietin og jernpræparater
AU7549787A (en) Isoliquiritigenin for the treatment of kidney and liver diseases
DE3582594D1 (de) Proglumid und dessen pharmazeutische zusammensetzungen zur anwendung bei der behandlung von neoplastischen affektionen.
NO931413L (no) Fremgangsmaater og preparater for behandling av celleproliferasjonssykdommer
DE3872881D1 (de) Arzneimittelzusammensetzung zur vorbeugung und behandlung bakterieller und viraler krankheiten.
ATE5256T1 (de) Phenylpiperazinderivate von 1,3,4oxadiazolylphenolen, ihre herstellung und diese enthaltende therapeutische mittel.
DK113789A (da) Thiosulfinsyrederivater, deres anvendelse til behandling af betaendelsessygdomme samt laegemiddel indeholdende disse stoffer
DK10188D0 (da) Middel til behandling af virussygdomme
ATE69949T1 (de) Liposomen mit inhalativen allergenen zur behandlung von allergien, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
ATE126437T1 (de) Verwendung von depogen zur behandlung von eingeschränktem blutkreislauf.
NO953003L (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater
JPS56125310A (en) Preparation of protein solution consisting essentially of lipoprotein of plasma with high specific gravity and serum albumin
RU93008439A (ru) Способ лечения хронического гнойного среднего отита
DK103087A (da) Middel til behandling af kroniske tilstoppende lungesygdomme

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PUP Patent expired